Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0020-7292(95)02478-U | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Alzheimer's disease (AD) presents unique challenges in clinical trials involving small molecules. Multifaceted issues plague such trials, emphasizing susceptibility to fraud from clinical sites and "professional patients". The relative ease of simulating Alzheimer's diagnosis, coupled with inadequate oversight by Contract Research Organizations (CROs), creates fertile ground for deceptive practices.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Brigham and Women's Hospital and Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
The most recent Alzheimer's clinical trials, including those which reported successful outcomes, use neuroimaging biomarkers of both amyloid and tau for screening participants and demonstrating a treatment effect on pathology. Some of these trials, notably Lecanemab, hint at a potential sex bias in treatment outcome, alluding to major implications for clinical practice when recommending treatment options. Sex differences in treatment response are not surprising given that women are at greater risk of progression to AD dementia, particularly if they carry APOEe4.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Neurology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Background: Integrating blood biomarker testing for Alzheimer's Disease (AD) into clinical practice has the potential to transform AD care by enabling broadly accessible and accurate diagnosis, more precise prognostication, and timely initiation of disease-modifying therapy. While there are several scientific challenges to implementing blood biomarkers (e.g.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.
Background: Up to 40% of current AD cases may have been preventable through protective factors, such as physical and cognitive activities, preventing neurodegeneration. Reserve, resilience, and resistance are key concepts in cognitive neuroscience of aging, and they share common adaptive mechanisms. In this paper we propose a development and validation of a new scale, called dynamic Neurocognitive Adaptation (dNA).
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
University of New Hampshire, Durham, NH, USA.
Background: There is a growing number of residents living with dementia (RLWD) in long-term care (LTC) settings, but dementia care access and quality are more limited in communities with fewer health resources and these limitations are exacerbated by current dementia care workforce shortages. Low-resource LTC settings, including poorer urban and rural settings, serve older adults who are at high risk for health inequities in dementia care. These settings can experience barriers in providing quality dementia care due to their limited ability to capture pertinent information about residents' needs and preferences and ensuring that information is known by dementia care staff.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!